PLoS One 8, e77306
It comes in four strengths (500 mg, 750 mg, 850 mg, and 1,000 mg), and a typical adult starts at one of the three lower doses once or twice daily, with gradual dose increases as needed
Individuals who may warrant closer monitoring include: Those with a personal or family history of depression , anxiety, or other mood disorders People who have previously experienced mood changes on other weight-loss medications or GLP-1-based therapies Individuals with eating disorders or a complex relationship with food , for whom appetite suppression may have psychological implications (see NICE guideline NG69: Eating disorders: recognition and treatment) [10] Those experiencing significant life stressors alongside starting a new treatment People with poorly controlled type 2 diabetes , where fluctuating blood glucose levels both hypoglycaemia and hyperglycaemia can independently affect mood, concentration, and emotional wellbeing It is also worth acknowledging that obesity itself is associated with higher rates of depression and anxiety, and that the psychological experience of rapid body weight change whether positive or negative can be emotionally complex
TRIUMPH-1 Phase 3 Results: A Promising Future The TRIUMPH-1 trial had impressive results, highlighting the potential of Retatrutide in the realm of weight management
Until final FDA rulemaking moves these peptides out of Category 2 and into Category 1 their regulatory status remains unchanged
